Home › Multiple Myeloma › Georgia
Multiple Myeloma clinical trials in Georgia
49 studies for Multiple Myeloma are looking for participants at sites in Georgia.
Cities in Georgia
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- City Of Hope - Atlanta /ID# 280294, Newnan
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Emory University Winship Cancer Center, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT04973605A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Emory University, Atlanta
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05201781A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Emory University - Winship Cancer Institute, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07393282A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
- Winship Cancer Institute Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06768489A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Emory University, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07258511A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- City of Hope Cancer Center, Newnan
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05552222A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07073547A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Emory University, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Emory University Winship Cancer Institute, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04634552A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Emory University Hospital, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America - Atlanta, Atlanta
- Emory University Winship Cancer Institute, Atlanta
- Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion, Savannah
- and 3 more
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Winship Cancer Institute of Emory University /ID# 277667, Atlanta
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07095452Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Winship Cancer Institute of Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04879043Collection of Tissue Samples for Cancer Research
- Emory University, Atlanta
RecruitingObservational study
2 Months · All sexes · Updated Sep 16, 2026 · NCT00900198A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Winship Cancer Institute, Emory University, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Winship Cancer Institute of Emory University, Atlanta
- Northside Hospital, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06297226Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Emory University Hospital Midtown, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07555938Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
- Emory University/Winship Cancer Institute, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT05208307A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Emory University Hospital, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07075185A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07681596A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Macon
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07227311AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT06106945A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- The Winship Cancer Institute of Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Winship Cancer Institute, Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Winship Cancer Institute, Emory University, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07284758Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
- Emory University Hospital/Winship Cancer Institute, Atlanta
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT07101445A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Winship Cancer Institute of Emory University /ID# 274830, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 21, 2026 · NCT06892522A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Northside Hospital, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06121843A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Winship Cancer Institute of Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT05137054Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Emory Winship Cancer Institute, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT04068597Personalized Autologous Transplant for Multiple Myeloma
- Winship Cancer Institute of Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 15, 2026 · NCT04483206Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
- Emory University Hospital/Winship Cancer Institute, Atlanta
Recruiting
Ages 18 and older · All sexes · Updated Jun 5, 2026 · NCT03858205Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Emory University Hospital, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT05243797Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Emory Winchip Cancer Center, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 19, 2026 · NCT06433947A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT06679101CAR T-cell Therapy in Patients With Renal Dysfunction
- Caitlin Guzowski, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT05909059From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.